Biogen Idec announced their intent to donate one billion international units (IUs) of clotting factor therapy for humanitarian aid programs in the developing world.
This donation is expected to enable a predictable, sustained humanitarian supply of factor therapy and improve the quality of patient care and outcomes in the developing world.
Biogen Idec and Sobi are partners in the development and commercialization of treatments for hemophilia. Biogen is responsible for product supply under the collaboration and Sobi, a specialty health care company headquartered in Stockholm, handles distribution.
Read the Biogen press announcement